Vascugen has brought on-board more licences related to stem cell therapies that could restore blood vessels in tissues where the blood flow has been restricted.
Vascugen, a US-based regenerative medicine developer spun out from Indiana University, has licensed additional intellectual properties from the institution’s School of Medicine.
The assets relate to using adult stem cells to restore the function of blood vessels. They align with Vascugen’s strategy of developing stem cell therapies for tissues affected by restricted blood flow because of disorders including peripheral artery disease, where cholesterol deposits in the arteries prevent blood from circulating to the limbs.
Vascugen said the new licences also cover…
